Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arthritis Res Ther. 2003;5(4):157-9. Epub 2003 Apr 15.

SLE - Rituximab in lupus.

Author information

  • Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. raemd@mail.med.upenn.edu

Abstract

B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled trials in SLE will be necessary to determine whether rituximab is useful therapy in this disease, and will teach us more about the roles of B cells in its pathogenesis.

PMID:
12823844
[PubMed - indexed for MEDLINE]
PMCID:
PMC165056
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk